Data in Richter’s transformation, Hodgkin lymphoma, Waldenström macroglobulinemia, and indolent lymphoma were presented at the 2020 ASCO Virtual Scientific Program, and although not entirely practice changing, are deserving of attention.
SLS009 plus venetoclax and azacitidine elicited responses in patients with relapsed/refractory AML, particularly in those harboring ASXL1 mutations.
The United States Preventive Services Task Force final breast cancer screening recommendation statement advises that women aged 40 begin biennial screening.
A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
Immunogenomic information displays predictive capability in terms of immunotherapy resistance in metastatic uveal melanoma.
Frontline pembrolizumab plus trastuzumab/chemotherapy improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.
Treatment with EVT801 was well tolerated and led to a stable disease rate of 46% in patients with advanced ovarian cancer.
Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study…
Dr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic…
Rezatapopt induced responses with acceptable toxicity in heavily pretreated patients with advanced ovarian cancer harboring TP53 Y220C mutations.
